Skip to content


Volume 9 Supplement 2

AIDS Vaccine 2012

Open Access

Isolation of a clonal lineage of IgA broadly neutralizing antibodies from a chronically infected Tanzanian subject

  • M Moody1,
  • MS Drinker1,
  • TC Gurley1,
  • JD Amos1,
  • JA Eudailey1,
  • LC Armand1,
  • R Parks1,
  • ES Gray2,
  • L Morris2,
  • A Finzi3,
  • X Yang3,
  • J Sodroski3,
  • H Liao1,
  • GD Tomaras1,
  • DC Montefiori1 and
  • BF Haynes1
Retrovirology20129(Suppl 2):O35

Published: 13 September 2012


Single CellLight ChainMucosal SurfaceContact RegionChain Gene


Only ~20% of HIV-1-infected subjects develop broadly neutralizing antibodies (bnAbs) and the origins of such antibodies remains obscure. To date, all isolated bnAbs have been of the IgG isotype.


Memory B cells from a chronically infected Tanzanian subject with plasma broad neutralizing activity were labeled with a consensus C envelope (Env) and Env+ cells sorted as single cells. Immunoglobulin heavy and light chain genes were amplified by PCR and analyzed for gene usage and isotype, and then were expressed as recombinant monoclonal antibodies (mAbs). MAbs were assayed for binding to Env proteins and for neutralization of multiple HIV-1 strains.


We isolated 13 mAbs that bound Env proteins; of these, 11 were members of three clonal lineages, each of which spanned two time points. Six mAbs in one lineage were all IgG1, used V H 1~69, had an average mutation frequency of 12%, mapped to the CD4 contact region, and had modest neutralization activity. In contrast, three mAbs in a second lineage had two members that were IgA2, used V H3~66, had an average mutation frequency of 16%, and neutralized 11/27 (41%) of tier 2 pseudoviruses tested.


We have isolated the first natural IgA mAbs with broad neutralizing activity. These data demonstrate that class switching to IgA can occur in the generation of bnAbs, an event that is essential for the generation of neutralizing IgA antibodies at mucosal surfaces.

Authors’ Affiliations

Duke University Medical Center, Durham, USA
National Institute for Communicable Disease, Johannesburg, South Africa
Dana-Farber Cancer Institute, Boston, USA


© Moody et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.